CHEMICAL/BIOLOGICAL DEFENSE (ATD)
Abstract
The projects in this program element (PE) demonstrate technologies supporting transition to advanced component development for physical capabilities which cover biological and chemical detection, situational awareness and effects modeling, and protection and hazard mitigation. Other major efforts support enhanced chemical detection capabilities for aerosols and non-traditional agents, expanded capabilities for early warning in pathogen detection and diagnosis, and pretreatments and therapeutics against a broader set of chemical and biological agents. Medical capabilities (pretreatments, therapeutics, diagnostics capabilities, and drug manufacturing and regulatory science technologies) include capabilities against non-traditional agents. Individual projects include: - Chemical Biological Defense (CB3): demonstrations of CB physical science defense technologies including biological detection, chemical detection, digital battlespace management, protection, and decontamination. - Emerging Threats (ET3): identify and develop scientific solutions, or to modernize capabilities, that allow for a more rapid response to emerging threats. - Non-Traditional Agents (NTA) Defense (NT3): supports all efforts (both medical and non-medical) including chemical diagnostics, medical pretreatments, therapeutics, detection, and protection and hazard mitigation. Starting in FY21, a portion of the NTA lines have been merged into RDT&E Projects CB3, Chemical Biological Defense, and TM3, Techbase Medical Defense. The administrative change is intended to improve S&T budget agility and transition efficiency. - Techbase Medical Defense (TM3): aims to produce biological diagnostic assays and reagents, diagnostic device platforms, pretreatments and therapeutics for bacterial, viral, and toxin threats as well as for chemical threats, and medical devices, as countermeasures for CBR threat agents. Specific areas of medical investigation include: prophylaxis, pretreatment, antidotes and therapeutics, personnel and patient decontamination, and medical management of casualties. - Technology Transition (TT3): validates high-risk/high-payoff technologies, concepts-of-operations, and a Joint Combat Developer concept development and experimentation process to significantly improve Warfighter capabilities in preparation for transition of mature chemical and biological (CB) defense technologies to advanced development programs. The CBDP S&T Advanced Technology Development stakeholders: The U.S. Army Combat Capabilities Development Command Chemical Biological Center (DEVCOM CBC), United States Army Medical Research Institute of Infectious Diseases (USAMRIID), United States Army Medical Research Institute of Chemical Defense (USAMRICD), United States Army Natick Soldier Systems Center, Naval Research Lab (NRL), Air Force Research Lab (AFRL), among others. The intent is to maintain strategic partnerships with the DoD Service communities for mission success across the enterprise through collaborative planning and programming maintaining budget assurance. Work conducted under this PE will transition to and will provide risk reduction for Advanced Component Development and Prototypes (PE 0603884BP) and System Development and Demonstration (PE 0604384BP) activities.
Document Details
- Document Type
- R2 Budgetary Justification
- Publication Date
- Oct 01, 2022
- Source ID
- 0603384BP_3_0400_PB_2022
- Change Summary Explanation
- Funding: FY20 (+$35.163 Million): Internal Reprogramming (FY20-31 IR) for the Coronavirus Aid, Relief, and Economic Security (CARES) Act (+$26.300 Million); below threshold reprogramming increase for COVID-19 SARS CoV-2 vaccine development project (+$5.404 Million), and medical defense pretreatments efforts (+$3.459 Million). FY20 (-$1.099 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts. FY21 (+$3.000 Million): Congressional Add for High Air Flow Chemical Biological (CB) Filtration System Enhancement. FY22 (+$9.345 Million): Increase for 1) Emerging Threat Rapid Response Capabilities, 2) COVID-19 SARS-CoV-2 vaccine development, and 3) to accelerate efforts to develop and deliver nerve agent medical countermeasures (+$12.111 Million). Departmental inflation/travel adjustments (-$2.766 Million). Schedule: N/A Technical: N/A
- Service Agency Name
- Chemical and Biological Defense Program
Related Documents
- Child Project: Chemical Biological Defense (ATD)
- Child Accomplishment: 1) CARES Act - Dial A Threat
- Child Accomplishment: 2) CARES Act - EpiGrid, Advanced Capabilities for Human Health Effects Modeling, Interior Modeling
- Child Accomplishment: 3) CARES Act - Rapid Detection and Identification of Biological Events Testing
- Child Accomplishment: 4) CARES Act - RATE Operationalization
- Child Accomplishment: 5) Expeditionary Collective Protection
- Child Accomplishment: 6) Air Purification Enhancements
- Child Accomplishment: 7) Respiratory and Ocular Protection
- Child Accomplishment: 8) All-Hazards & Respiratory Protection
- Child Accomplishment: 9) Multifunction Materials for Protection
- Child Accomplishment: 10) Warning and Reporting
- Child Accomplishment: 11) CBRN Battlespace Surveillance, Alerting & Response
- Child Accomplishment: 12) Decision Analysis and Management
- Child Accomplishment: 13) CBRN Decision Aids
- Child Accomplishment: 14) CBRN Situational Awareness
- Child Accomplishment: 15) Detection
- Child Accomplishment: 16) Distributed CB Reconnaissance
- Child Accomplishment: 17) Enhanced/Emerging Biothreat Sensing
- Child Accomplishment: 18) Expeditionary Analytical Toolkit (ExAnT)
- Child Accomplishment: 19) Unattended Perimeter Monitoring
- Child Accomplishment: 20) Unconventional Detection Modalities
- Child Accomplishment: 21) Percutaneous Protection
- Child Accomplishment: 22) Lightweight Protective Garments
- Child Accomplishment: 23) Dynamic Multifunction Materials for Second Skin
- Child Accomplishment: 24) Material Contamination Mitigation
- Child Accomplishment: 25) Enhanced Survivability Coatings
- Child Accomplishment: 26) Equipment Decontamination
- Child Accomplishment: 27) Personnel Decontamination
- Child Project: Emerging Threats (ATD)
- Child Accomplishment: 1) Emerging Threat Innovation
- Child Project: Non-Traditional Agents Defense (ATD)
- Child Accomplishment: 1) Material Contamination Mitigation
- Child Accomplishment: 2) Modeling & Simulation
- Child Accomplishment: 3) Percutaneous Protection
- Child Accomplishment: 4) Personnel Contamination Mitigation
- Child Accomplishment: 5) Respiratory and Ocular Protection
- Child Accomplishment: 6) Test & Evaluation
- Child Accomplishment: 7) Therapeutics - Medical
- Child Accomplishment: 8) Pretreatments and Prophylactics - Medical
- Child Accomplishment: 9) Detection
- Child Accomplishment: 10) Distributed CB Reconnaissance
- Child Accomplishment: 11) Expeditionary Analytical Toolkit (ExAnT)
- Child Accomplishment: 12) Unconventional Detection Modalities
- Child Project: Techbase Medical Defense (ATD)
- Child Accomplishment: 1) CARES Act - A Highly Multiplexed Point-of-Care Digital Protein Assay Platform with Digital Molecular Capability
- Child Accomplishment: 2) CARES Act - Host Response (Organs-on-chips)
- Child Accomplishment: 3) CARES Act - SARS COV-2 VSV vaccine
- Child Accomplishment: 4) Internal COVID - New Horizons Diagnostics Corporation - Serology
- Child Accomplishment: 5) Internal COVID - Serology Development and IV&V Testing
- Child Accomplishment: 6) Internal COVID - Systems Approach to Medical Countermeasures Development
- Child Accomplishment: 7) Internal COVID - Systems Approach to Medical Countermeasures Development
- Child Accomplishment: 8) Internal COVID - VSV SARS CoV-2 vaccine
- Child Accomplishment: 9) Medical Diagnostics
- Child Accomplishment: 10) Battlefield Readiness
- Child Accomplishment: 11) Battlefield Readiness
- Child Accomplishment: 12) Chemical Diagnostics
- Child Accomplishment: 13) Chemical Diagnostics
- Child Accomplishment: 14) Clinical Evaluation
- Child Accomplishment: 15) Emerging Threats
- Child Accomplishment: 16) Diagnostic Building Blocks
- Child Accomplishment: 17) Vaccine Platforms and Research Tools
- Child Accomplishment: 18) Viral Vaccines
- Child Accomplishment: 19) Bacterial/Toxin Vaccines
- Child Accomplishment: 20) Bacterial, Viral and Toxin Prophylaxis
- Child Accomplishment: 21) Chemical Therapeutics
- Child Accomplishment: 22) Nerve Agent Prophylaxis/Pretreatments
- Child Accomplishment: 23) Pharmaceutical Based Agents (PBAs)
- Child Accomplishment: 24) Reactivators of AChE as Therapeutics (ReACT)
- Child Accomplishment: 25) Bacterial Therapeutics
- Child Accomplishment: 26) Viral Therapeutics
- Child Accomplishment: 27) Toxin Therapeutics
- Child Accomplishment: 28) Medical Countermeasures Initiative
- Child Accomplishment: 29) Laboratory Operations & Support
- Child Project: Technology Transition (ATD)
- Child Accomplishment: 1) Experiment & Technology Demonstrations
- Child Accomplishment: 2) Advanced Technology Demonstration
- Child Accomplishment: 3) Technology Concept
- Child Accomplishment: 4) User Assessment